Sumitomo Pharma Co., Ltd. (4506.T) JPX
1,472.50
-21.5(-1.44%)
Currency In JPY
- General
- Statistics
- Historical Data
- Profile
- Financials
Sumitomo Pharma Co., Ltd.
Address
6-8 Doshomachi 2-chome
Osaka, 541-0045
Japan
Phone
81 6 6203 5321
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
4980
First IPO Date
January 04, 2000
Key Executives
| Name | Title | Pay | Year Born |
| Toru Kimura | Representative Director, President & Chief Executive Officer | 101M | 1960 |
| Megumi Maruyama | Vice President & Head of Corporate Communications | 0 | N/A |
| Katsuhiko Nishida | EO, SVP of S&M & Head of Japan BU Deputy | 0 | N/A |
| Hideyuki Harada | Mng. Exe. Off. of Supply Chain Div., SVP, Hd. of Supply Chain Div. & Hd. of Japan Bus. Unit | 0 | N/A |
| Koji Yamazaki | Exec. Off. of Sales & Mark. Div., SVP, Hd. of Sales & Mark. Div. Dep. Hd. of Japan Bus. Unit | 0 | N/A |
| Isao Shimizu | Exec. Off.,SVP, Dep. Head of R&D Div. & Corp. Reg.Comp & Quality Assurace. Div. | 0 | N/A |
| Tsutomu Nakagawa | Managing Executive Officer & Director | 0 | 1968 |
| Kimihiro Mizuno | Executive Officer Legal & Compliance and Intellectual Property | 0 | N/A |
| Shunji Kobayashi | Executive Officer of Human Resources | 0 | N/A |
| Kenji Ueno | Executive Officer, Senior Vice President and Deputy Head of Research and Development Division (CMC) | 0 | N/A |
| Koichi Kozuki | E.O. of Corp. Reg. Comp., Bus Dev mgmt & Q.A., Sr. VP, Hd of C.R.C. & Q.A. Div & Dp. Hd of Jap. Bus. | 0 | N/A |
| Motoyuki Sakai | EVP of Glob. C.ST., Glob. Fin. Admin. Ext. Aff., Corp. Gov. Corp. Com, IT Mngt., DA & Rep. Dir | 0 | 1961 |
| Yumi Sato | Managing Exe. Officer of Research & Dev. Div. Senior Vice President and Head of Research & Development Division | 0 | N/A |
Description
Sumitomo Pharma Co., Ltd. manufactures and sells pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally. The company offers pharmaceutical products, such as therapeutic agents for Parkinson's disease, depression, type 2 diabetes, systemic fungal infection, hypertension, pruritus, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It also provides products for atypical antipsychotic, antiepileptic, carbapenem antibiotic, and gastrointestinal; and Anderson-Fabry disease drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, as well as seasonings, such as soups or bouillons; and chemical product materials, which include pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, such as dogs and cats; and livestock comprising cattle, swine, poultry, horses, and aquacultured fish. Sumitomo Pharma Co., Ltd. has partnerships with Healios K.K.; Keio University; RIKEN; the Center for iPS Cell Research and Application; Kyoto University; and Aikomi Co., Ltd., as well as a joint development agreement with SanBio Company Limited; and collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. It also has a strategic alliance with Roivant Sciences Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was founded in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.
